IVIXF (Invion) Days Payable: 0.00 (As of Dec. 2025)

What is Invion Days Payable?

Invion IVIXF -83.23% 16 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates IVIXF with a GF Score™ of 16/100 and a GF Value™ of $0.17. The stock has 2 warning signs investors should review. Among 923 Drug Manufacturers companies, Invion ranks worse than 108342.25% on this metric.

Invion's average Accounts Payable for the six months ended in Dec. 2025 was $0.64 Mil. Invion's Cost of Goods Sold for the six months ended in Dec. 2025 was $0.00 Mil.

The historical rank and industry rank for Invion's Days Payable or its related term are showing as below:

IVIXF's Days Payable is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 90.98
* Ranked among companies with meaningful Days Payable only.

Invion's Days Payable stayed the same from Dec. 2024 (0.00) to Dec. 2025 (0.00).

Invion Days Payable Related Terms

Invion Days Payable Historical Data

* Premium members only.

The historical data trend for Invion's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invion Days Payable Chart

Invion Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

Days Payable

Get a 7-Day Free Trial

0.00

Invion Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

IVIXF vs ZTS, UTHR: Days Payable Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Invion's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invion Days Payable vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Invion's Days Payable distribution charts can be found below:

* The bar in red indicates where Invion's Days Payable falls into.

Save Embed

16GF Score

Invion Ltd IVIXF

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Invion Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Invion's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as

	Days Payable (A: Jun. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2024 )	+	Accounts Payable (A: Jun. 2025 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2025 )	*	Days in Period
=	( (0.479	+	0.354)	/	2 )	/	0	*	365
=	0.4165					/	0	*	365
=	N/A

Invion's Days Payable for the quarter that ended in Dec. 2025 is calculated as:

	Days Payable (Q: Dec. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2025 )	+	Accounts Payable (Q: Dec. 2025 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2025 )	*	Days in Period
=	( (0.354	+	0.926)	/	2 )	/	0	*	365 / 2
=	0.64					/	0	*	365 / 2
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

Invion (IVIXF) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Invion and its competitors. According to the industry distribution chart, Invion ranks #999999 out of 923 companies in the Drug Manufacturers industry.

Is Invion's Days Payable too high?

Invion's current Days Payable is 0.00. Based on the distribution chart, Invion ranks #999999 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Invion has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.

How does Invion's Days Payable compare to ZTS and UTHR?

According to the Drug Manufacturers industry distribution chart, Invion ranks #999999 out of 923 companies for Days Payable. This places Invion in the lower half of its industry. The industry median Days Payable is 90.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Drug Manufacturers company?

The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Invion and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invion's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Invion stock overvalued right now?

Invion (IVIXF) has a current Days Payable of 0.00. The stock's GF Value™ is $0.17, compared to a current price of $0.04 — trading 78.3% below its estimated fair value. The current Days Payable is 0.00. Invion's overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Invion (IVIXF), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Invion (IVIXF) Overvalued in 2026?

Based on GuruFocus' analysis, Invion stock appears to be undervalued. The current stock price of $0.04 is trading 78.3% below its estimated GF Value™ of $0.17.

Key valuation signals for IVIXF:

Days Payable: 0.00
GF Value™: $0.17 vs. price of $0.04 (78.3% below fair value)
GF Score™: 16/100 with 2 warning signs

No single metric tells the full story. See the IVIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Invion Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies ASX:RGT ASX:BP8 ASX:EXL ASX:CAN ASX:PER ASX:ECS ASX:EPN ASX:IDT ASX:PKP XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692 UTHR

Other Exchanges 7C8:Germany IVX:Australia

Address 692 High Street, East Kew, VIC, AUS, 3102

Website https://www.inviongroup.com

Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers, and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.

16GF Score

Get the complete analysis for IVIXF

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.04

Price

$0.17

GF Value

View IVIXF Analysis

See Days Payable data for all stocks →